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Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer
Aims: Lymphovascular space invasion (LVSI) in
endometrial cancer (EC) is an important prognostic
variable impacting on a patient’s individual recur-
rence risk and adjuvant treatment recommendations.
Recent work has shown that grading the extent of
LVSI further improves its prognostic strength in
patients with stage I endometrioid EC. Despite this,
there is little information on the reproducibility of
LVSI assessment in EC. Therefore, we designed a
study to evaluate interobserver agreement in discrimi-
nating true LVSI from LVSI mimics (Phase I) and
reproducibility of grading extent of LVSI (Phase II).
Methods and results: Scanned haematoxylin and
eosin (H&E) slides of endometrioid EC (EEC) with a
predefined possible LVSI focus were hosted on a
website and assessed by a panel of six European
gynaecological pathologists. In Phase I, 48 H&E slides
were included for LVSI assessment and in Phase II,
42 H&E slides for LVSI grading. Each observer was
instructed to apply the criteria for LVSI used in daily
practice. The degree of agreement was measured
using the two-way absolute agreement average-mea-
sures intraclass correlation coefficient (ICC). Repro-
ducibility of LVSI assessment (ICC = 0.64, P < 0.001)
and LVSI grading (ICC = 0.62, P < 0.001) in EEC
was substantial among the observers.
Conclusions: Given the good reproducibility of LVSI,
this study further supports the important role of LVSI
in decision algorithms for adjuvant treatment.
Keywords: endometrial neoplasms, interobserver study, LVSI, LVSI grading, lymphovascular space invasion,
observer variation
Introduction
Classic histopathological parameters are the corner-
stone of the current risk-assessment and guide
adjuvant treatment for patients with early-stage
(stages I/II) endometrial carcinoma (EC). Tumour fac-
tors included in the risk assessment of early-stage dis-
ease are histological type, tumour grade, cervical
stromal involvement, depth of myometrial invasion
and lymphovascular space invasion (LVSI). Combina-
tions of these factors stratify early-stage EC patient
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into low-risk (LR), high–intermediate risk (HIR) and
high-risk (HR) for recurrence with differential adju-
vant treatment choices.1–3
Currently, significant advances in our understand-
ing of molecular alterations in EC are reshaping the
risk assessment by incorporating molecular features.
Novel models in which molecular factors are inte-
grated to further refine the risk assessment are being
developed.4,5 These integrated approaches still rely on
the most relevant histological variables mentioned
above. The Achilles heel of those histological vari-
ables, however, is the reproducibility among patholo-
gists. One of the strongest prognostic variables in this
context is the presence (or absence) of LVSI.
LVSI has gained a prominent position in most of the
risk stratification systems for EC.5–7 Adjuvant radiation
treatment for patients with grade 1 or 2 stage I EEC is
recommended in the presence of LVSI, independent of
the depth of myometrial invasion.7 It is interesting that
the adjective ‘unequivocal’ is used for LVSI in the most
recent ESMO–ESTRO–ESGO (European Society for Med-
ical Oncology–European Society for Radiotherapy and
Oncology–European Society of Gynaecological Oncol-
ogy) clinical guidelines,7 as it advises to report LVSI
only when there is no other interpretation possible.
This immediately evokes the question of ‘how repro-
ducible among pathologists is unequivocal LVSI’. In
addition, recent work shows that substantial LVSI in
EC may have a stronger prognostic significance than
focal LVSI;8,9 similar effects are reported for LVSI grad-
ing in breast cancer.10
A diversity of LVSI definitions can be found in the
EC literature, reflecting different ways to approach its
assessment. Irrespective of the exact formulation, all
these refinements are aimed to help distinguish LVSI
from LVSI mimics. The most frequently encountered
LVSI mimic is artefactual displacement of tumour
within myometrial clefts or large endothelial-lined
vessels. These displacements are probably the result
of manipulation of the uterus by an intrauterine bal-
loon during surgery11 or an artefact induced by inap-
propriate grossing of a friable tumour.12 Artefactual
displacement is more likely to occur in cases with
poor fixation or in EC with abundant necrosis.
Another frequent artefact that mimics LVSI is stromal
retraction around invading tumour glands. Further-
more, ‘emboli’ in vascular spaces are not always
clearly composed of viable tumour cells. There may
be degenerative changes, and infiltration of inflamma-
tory cells may obscure the presence of tumour cells
in these emboli. A specific type of myometrial inva-
sion, referred to as ‘microcystic elongated and frag-
mented (MELF)-type invasion’,13 may also be
confused with LVSI, but importantly is also associated
with true LVSI. Additional histological criteria, such
as proximity to a venous and arterial vessel10 or
perivascular lymphocytes, have been proposed to
favour true LVSI.14
The reported prevalence of LVSI in stage I EC varies
widely (3.2–35%), indicating that there may be local
differences in how LVSI assessment is conducted and
reported;15,16 however, interobserver variability stud-
ies focusing on LVSI in EC are sparse. Given the sig-
nificance of LVSI evaluation in risk allocation of EC,
and the widely accepted difficulties in LVSI assess-
ment, this study was initiated to examine interob-
server agreement on the presence of LVSI and LVSI
grading. To our knowledge, this is the first study to
assess the reproducibility of the recently proposed
grading system for LVSI.
Materials and methods
In a previous study,8 haematoxylin and eosin (H&E)
stained slides of EEC from 926 patients derived from
the PORTEC 1 and 2 trials2,17 were locally re-re-
viewed for the presence of LVSI by the study patholo-
gists (E.E.M.P., T.B. and V.T.H.B.M.S.). At review, the
presence of LVSI mimics was also noted.
In Phase I, to determine agreement of LVSI assess-
ment, 48 cases were selected by the study pathologists,
composed of challenging LVSI mimics (n = 29) and
cases with convincing true LVSI (n = 19). The LVSI
mimics were composed of MELF (n = 8); retraction arte-
fact (no endothelial lining) (n = 10); artefactual tumour
displacement (n = 5); and LVSI mimics of emboli with-
out tumour cells (n = 6). H&E slides were scanned and
hosted on a website designed for this purpose. To ensure
that all observers evaluated the same focus, they were
guided to the predefined, digitally annotated putative
LVSI focus. It remained possible for the observers to
view the whole section and not just the preselected
focus by scrolling through the complete scanned slide.
In this phase observers were asked to indicate if the
selected focus was true LVSI, using the LVSI definition
they used in daily practice. When observers did not con-
sider the marked focus as true LVSI, they were asked to
specify what type of LVSI mimic was present (Support-
ing information, Table S1A). In this phase we also asked
the observers to explain their choice. We also asked the
observers for the definition of LVSI that they used in
everyday practice.
In Phase II, we set out to determine agreement of
LVSI grading. For this, a new selection of 42 cases was
put together by the study pathologists. All 42 cases
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were considered positive for true LVSI on re-review
and were graded as either focal (n = 20) or substantial
LVSI (n = 22). Cases were presented to the same group
of observers on the same website, asking them first to
confirm LVSI and next to grade LVSI-positive cases as
either focal LVSI or substantial LVSI. Focal LVSI was
defined semiquantitatively as ‘the presence of a single
focus of LVSI around the tumour’. Substantial LVSI
was defined as ‘diffuse or multifocal LVSI around the
tumour’ (Supporting information, Table S1B).18 Free
text comments were optional.
Six experienced gynaecological pathologists (ob-
servers) were recruited via the European Network for
Individualised Treatment of Endometrial Cancer (ENI-
TEC) network. We aimed to include pathologists of
different nationalities and from different European
institutes in order to assure differing training back-
grounds.
S T A T I S T I C S
Raw data were stored on the website, downloaded
and processed prior to analysis. Agreement among
observers was measured using the two-way absolute
agreement average-measures intraclass correlation
coefficient (ICC). Due to the lack of a gold standard
for true LVSI, this method results in a measure of
intraobserver and interobserver variability.19 The SPSS
version 23.0 package was used for statistical analy-
ses. An ICC value reflects slight (0–0.19); fair (0.2–
0.39); moderate (0.4–0.59; substantial (0.6–0.79); or
almost perfect (> 0.8) agreement. Additionally, agree-
ment was qualitatively expressed as: ‘full agreement’
when all observers agreed; ‘partial agreement’ when
four or five observers agreed and ‘no agreement’
when three or fewer observers agreed.20
Results
Table 1 lists the LVSI definitions provided by the
gynaecological pathologists (observers). These defini-
tions all capture the key element of the consensus
definition of LVSI; namely, the presence of tumour
cells in a vessel lined by endothelial cells. Some obser-
vers also include exclusion criteria or components,
such as adherence to the vessel wall and the presence
of erythrocytes.
P H A S E I : R E P R O D U C I B I L I T Y O F L V S I A S S E S S M E N T
Full agreement concerning the presence or absence of
LVSI was found in 10 of 48 cases (21%); partial
agreement in 23 cases (48%); and no agreement in
15 cases (31%) (Table 2). Individual scores are pre-
sented in Supporting information, Table S2. One
observer was a noted outlier and appeared to have a
low threshold for diagnosing true LVSI. Overall, these
outcomes resulted in substantial agreement
(ICC = 0.6, P < 0.001) in LVSI assessment.
Some representative examples of LVSI mimics from
the study are illustrated in Figure 1. Interestingly,
there was little agreement on the various reasons to
score the focus as negative for LVSI. There were 26
cases in which at least two observers stated there
was no LVSI. In just eight of these cases (31%) the
same explanation was given. In the remaining 18
cases (69%) at least two different reasons for ‘no
LVSI’ were given. This is illustrated in Figure 2, a
case in which mimics co-exist resulting in more than
one reason to reject true LVSI.
P H A S E I I : R E P R O D U C I B I L I T Y O F L V S I G R A D I N G
Full agreement was achieved in six cases (14%); par-
tial agreement in 23 cases (55%); and no agreement
in 13 cases (31%) (Table 2). Figure 3 is an example
of a case with full agreement on focal LVSI. Figure 4
illustrates a case with partial agreement on substan-
tial LVSI. The overall reproducibility in this phase
was moderate (ICC = 0.54, P < 0.001). However,
Table 1. Definitions of LVSI as used by the observers
Observer What definition of LVSI do you use in daily practice?
A Cohesive aggregates of tumour cells located inside a
vascular space (defined by the presence of an
endothelial lining) and preferentially juxtaposed to the
vessel wall
B Carcinoma cells adherent to vessel wall (with
endothelial cells)
C Definite tumour cells within an endothelial lined
channel and no features to suggest artefactual
vascular invasion
D Presence of tumour cells in lymphatics or vessels, which
is not caused by artefacts (such as smears, retraction)
E Tumour cells usually as a group or nest within a space
that is covered by endothelial cells and does not
contain a significant number of erythrocytes
F The presence of a tumour embolus within a vessel
(capillary or lymphatic), usually well defined, rounding
up to the contour of the vessel, may or may not be
attached to the inner surface, may include red cells or
fibrin; absence of marked autolysis
LVSI, lymphovascular space invasion.
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one pathologist consistently scored cases as negative
for LVSI, whereas two pathologists had a noted ten-
dency to diagnose substantial LVSI. Individual scores
are presented in Supporting information, Table S3.
LVSI grading in cases recognised by the observers as
true LVSI resulted in substantial agreement
(ICC = 0.62, P < 0.001) using the predefined semi-
quantitative definitions for grading LVSI.
Table 2. Qualitative level of agreement in LVSI assessment (Phase I) and LVSI grading (Phase II), according to initial central
review
Level of agreement
Phase I Phase II
Initial review
LVSI-positive(n = 19)
Initial review
LVSI-negative(n = 29)
Initial review
focal LVSI(n = 20)
Initial reviewsubstantial
LVSI (n = 22)
Full 5 5 3 3
Partial 10 13 11 13
None 4 11 6 6
LVSI, lymphovascular space invasion.
A B
C D
Figure 1. Representative
examples of lymphovascular
space invasion (LVSI) mimics
presented in Phase I. A,
Retraction artefact around
poorly preserved invading
tumour. B, A cluster of
inflammatory cells within a
vessel, mimicking tumour cells.
C, A microcyst aligned by
flattened epithelial cells with a
cluster of tumour cells in the
centre, mimicking true LVSI.
D, A cluster of tumour cells
trapped within a myometrial
cleft without an endothelial
lining. Note the lack of
perivascular infiltrate in all
LVSI mimics.
© 2019 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 75, 128–136.
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Discussion
In this study we explored the interobserver repro-
ducibility in both diagnosing LVSI and in the applica-
tion of a recently introduced LVSI grading system.8
As the presence of LVSI is considered one of the
strongest predictors of recurrence in early-stage EC, it
is critical to assess reproducibility and identify prob-
lematic areas to further improve LVSI assessment.
Here, we show that gynaecological pathologists reach
substantial agreement in LVSI assessment.
We did not provide the observers with a LVSI defi-
nition, because a consensus definition for LVSI in the
literature is lacking. A variety of elements in the defi-
nition of LVSI can be found in the literature, such as
the presence of an endothelial lining,21 use of ancil-
lary studies,22–24 position of the LVSI focus relative to
the tumour,25 attachment of the embolus to the ves-
sel wall or not,26,27 the nature of the vessel (lym-
phatic, vascular, ‘capillary-like’),25,28,29 vitality and
shape of the embolus30 and presence of surrounding
erythrocytes31 or perivascular infiltrates.14 We did,
however, ask our observers to provide the LVSI defi-
nition they use in their daily practice. These defini-
tions showed significant overlap, and all LVSI to be
defined as ‘tumour cells’ located in a ‘vessel’. The
minor differences in refinements to this definition are
unlikely to be a source of varying interpretations.
A
B
Figure 2. A representative example of a case with no consensus on lymphovascular space invasion (LVSI) assessment. This case shows two
suspected foci of LVSI close to each other. The lower focus (A) shows the presence of endothelial cells indicating that this is a vessel; how-
ever, the cell cluster within this vessel does not unequivocally contain tumour cells. The upper focus (B) shows a vessel with a cluster of
epithelioid cells infiltrated by a few lymphocytes. Three observers scored this case as LVSI-positive, two scored negative, arguing the lack of
tumour cells, one scored negative because of the lack of endothelial cells. In this case subsequent immunohistochemistry (IHC) would proba-
bly result in a higher level of agreement.
Figure 3. A case derived from Phase II with full agreement on
focal lymphovascular space invasion (LVSI). The overview shows
infiltrating tumour glands surrounded by an extensive stromal
reaction. Some glands are surrounded by retraction artefacts.
There is a focus top right (detail shown left) suspected for LVSI.
The focus contains a perivascular lymphocytic infiltrate and is
adjacent to a venule. This was the only LVSI focus on this
haematoxylin and eosin (H&E). All observers graded this as focal
LVSI. [Colour figure can be viewed at wileyonlinelibrary.com]
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With this study, we add to previous studies regard-
ing reproducibility of pathological reporting of other
EC specific characteristics such as histological typing,
tumour grading, assessment of cervical involvement
and assessment of myometrial invasion.32–35 Levels of
reproducibility of these tumour characteristics are
similar to our results for LVSI assessment. None of
the previous studies specifically focused on LVSI
assessment, but there are two studies that report on
reproducibility of LVSI in EC.33,36 LVSI and other
tumour characteristics were reviewed as part of an
upfront pathology review before randomisation in the
PORTEC-3 trial.36 A high rate of interobserver agree-
ment between the original pathology report and cen-
tral pathology review was found for LVSI (j = 0.72).
In the study by Guan et al., LVSI assessment was part
of an alternative binary grading system in EC.33 Here,
LVSI was defined as clusters of malignant epithelial
cells within vascular spaces located outside the main
tumour. Assessment was performed on H&E slides
and CD31 was used to identify the endothelial lining
in indeterminate or suspicious cases. Assessment of
254 EC by four pathologists resulted in a disappoint-
ing j-value of 0.23 for LVSI. Several explanations
may be considered as to why our study resulted in
much higher j-values. First, LVSI was one parameter
among three others, making observers less focused on
one particular parameter. Secondly, in our study
observers were guided to a predefined focus, ensuring
that all observers examined the same area of interest.
Lastly, the observers in our study were selected based
on their special interest in gynaecological pathology,
with the assumption that they are familiar with com-
mon LVSI mimics in EC.
Some of the observers in our study commented that
they would have used immunohistochemistry (IHC)
to prove the presence of endothelial cells in a subset
of the presented cases. Although the role of adding
IHC to LVSI assessment was not part of the study
design, it seems obvious that difficult cases may bene-
fit from the use of IHC. Appropriate IHC to help
demonstrate LVSI are pan-endothelial (CD31) or
lymph vessel-specific (podoplanin/D2-40) antibodies.
Weber et al. found that D2-40 IHC increases the pro-
portion of LVSI-positive cases in EC compared to H&E
evaluation alone. Interestingly, all D2-40-positive
cases could be identified retrospectively on H&E.37
Alexandre-Sefre et al. compared routine H&E LVSI
detection with dual pancytokeratin and CD31 stain-
ing, and found a threefold increase in the LVSI detec-
tion rate from 18% with H&E to 54% using IHC in
stage I EC.24 However, both studies failed to illustrate
how the increased detection with IHC would affect
the clinical relevance/prognostic strength of LVSI
detection. There may also be reasons to be reluctant
to apply IHC universally. Cancer-associated fibroblasts
surrounding adenocarcinoma of the lung38 and
breast39 have been shown to express podoplanin.
A
B
C
D
E
Figure 4. A case derived from
Phase II with partial
agreement on substantial
lymphovascular space invasion
(LVSI). Box T shows a detail of
the endometrioid endometrial
cancer (EEC) with a prominent
peritumoral infiltrate. Insets A–
E show details of putative LVSI
foci that were annotated for
this case, that was called
substantial LVSI by the study
pathologist. Five observers
diagnosed this case as positive
for LVSI and four agreed to
grade this as substantial LVSI.
[Colour figure can be viewed at
wileyonlinelibrary.com]
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Although non-specific fibroblastic reactivity was not
described in the studies by Weber et al. and Alexan-
dre-Sefre et al., it is possible that an extensive fibrob-
lastic reaction in EC (e.g. in the MELF-infiltrative
growth pattern) could exhibit podoplanin positivity
and results in an incorrect diagnosis of LVSI. Further-
more, Harris et al, showed that the assessment of
both small- and large-vessel involvement in colorectal
carcinoma could not be improved by application of
D2-40 and CD31.40 We acknowledge, however, that
the use of IHC can be useful in selected difficult cases
(e.g. cases with extensive retraction artefact), and
when used in the correct context will probably fur-
ther improve interobserver agreement.
Reproducibility of LVSI assessment has also been
studied in the context of other tumours, such as hep-
atocellular carcinoma (HCC),41 colorectal cancer40
and squamous cell carcinoma of the floor of the
mouth.42 In the HCC study,41 inter- and intraob-
server reproducibility of six pathologists were anal-
ysed. LVSI definitions were not provided and 126
slides and 26 images were circulated twice among
the observers. There was moderate overall agreement
in both attempts (first round j = 0.50, second round
j = 0.43), with slightly lower agreement among non-
hepatopathologists compared to hepatopathologists. A
study in colorectal cancer40 included 50 cases from
which one H&E slide circulated among six gastroin-
testinal pathologists assessing small- and large-vessel
invasion using the individual pathologists’ own crite-
ria. The agreement for small-vessel invasion on H&E
slides was fair (j = 0.28). Agreement was not
improved with the use of CD31 (j = 0.26) or D2-40
(j = 0.32). LVSI assessment in squamous carcinoma
of the floor of the mouth42 was performed on H&E
slides from 58 cases by three pathologists using their
own criteria. This resulted in substantial agreement
for LVSI (j = 0.64), comparable to our findings. The
variation in levels of agreement between these studies
shows that reproducibility of LVSI assessment is prob-
ably tumour type-specific.
A three-tiered LVSI grading system for EEC (no,
focal, substantial) has only recently been proposed.8
Despite its novelty, this study showed that the obser-
vers were able to apply the semiquantitative system
with good agreement. Focal LVSI was defined as ‘a
single focus of LVSI around a tumour’ and substan-
tial LVSI was defined as ‘diffuse or multifocal LVSI
around a tumour’. Given the considerable repro-
ducibility of this system, this seems a very reasonable
approach in daily practice. We do, however, recog-
nise that problematic cases exist in which this semi-
quantitative approach may not suffice. For example,
cases with two to five involved vessels, clustered in a
small focus, may be regarded as ‘focal’ by some (if
assumed that all the foci of LVSI involve a single ves-
sel) and ‘substantial’ by others. Although this sce-
nario is rare and therefore will be a minor problem in
practice, the grading system may benefit from more
precise cut-off values. One would anticipate that this
would result in further improvement of the repro-
ducibility. At the time of this study, no evidence-
based cut-off values were available.
Like all interobserver studies, this study is not with-
out its limitations. Importantly, given the lack of a
gold standard, we had to rely on the assessment of
the study pathologists for case selection. The study
cohort was enriched for cases with potential LVSI,
including a selection of LVSI artefacts and mimics,
and therefore represents a selected and diagnostically
difficult cohort. The level of interobserver agreement
in this study, therefore, probably represents an under-
estimation of the true agreement for LVSI assessment
in EC. A more realistic unselected routine cohort
would include many LVSI-negative cases without
artefacts or mimics, which would probably result in a
much higher agreement. Furthermore, we did not
provide serial sections or additional stains to the
observers, which in selected cases may have
improved agreement.
In summary, this study shows that gynaecological
pathologists are able to adequately discriminate
unequivocal LVSI from LVSI mimics. LVSI grading
using a recently proposed three-tiered system (no,
focal, substantial) was reproducible. Given the prog-
nostic relevance,8 this study further supports the
implementation of this LVSI grading system to rou-
tine clinical practice.
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